Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bullish +45

BioNTech’s Double Play: Cancer Vaccine Milestone and a New Legal Front Against Moderna

📊 BioNTech's personalized mRNA cancer vaccine, Autogene Cevumeran (BNT122), showed a striking six-year survival rate of 87.5% in pancreatic cancer patients who mounted an immune response.

🏥 Among non-responders to the vaccine, only 25% survived the same period with a median overall survival of 3.4 years.

⏳ The T-cells triggered by the vaccine have an estimated average lifespan of 7.7 years, suggesting potential for long-term immunological surveillance against cancer recurrence.

🧬 Each dose is custom-manufactured based on a patient's tumor DNA profile, encoding up to 20 patient-specific neoantigens.

⚖️ BioNTech's subsidiary CureVac filed a patent infringement lawsuit in Delaware federal court against Moderna regarding Spikevax mRNA stabilization technology.

💰 The German biotech group is seeking licensing fees from Moderna as part of the legal dispute over intellectual property.

📉 BioNTech shares closed Friday at €88.75, up roughly 16% over the past month despite a recent lowered 2026 revenue forecast.

📈 Wall Street analysts rate BioNTech shares with a consensus "Moderate Buy" rating and an average price target of $133.

🚀 The company is targeting 15 Phase 3 oncology studies running by the end of 2026, with up to seven late-stage clinical data packages expected this year.

🎯 Meaningful oncology revenue is not anticipated until after 2026, but the goal of becoming a multi-product oncology company by 2030 remains intact.

🗓️ Investors should note first-quarter results due on May 5 and an annual general meeting proposal to expand the supervisory board to eight members.

Bullish Signals
  • BioNTech reported a striking seven-year survival milestone with its personalized mRNA cancer vaccine Autogene Cevumeran, where seven out of eight patients remained alive six years after surgery for pancreatic ductal adenocarcinoma.
  • Among responders to the personalized mRNA cancer vaccine, 87.5% of patients were still alive at the last follow-up, compared to a much lower survival rate in non-responders.
  • The T-cells triggered by BioNTech's vaccine carry an estimated average lifespan of 7.7 years, suggesting the mRNA approach could enable long-term immunological surveillance against cancer recurrence.
  • A global Phase 2 trial for Autogene Cevumeran is already underway following positive Phase 1 data presented at the AACR Annual Meeting 2026.
  • BioNTech shares have rallied nearly 19 percent over the past 30 days, trading above its closely watched 200-day moving average at €88.75.
  • Eighteen analysts rate BioNTech shares a consensus 'Moderate Buy' with an average price target of $133.
  • The company is targeting 15 Phase 3 oncology studies running by the end of 2026, with up to seven late-stage clinical data packages expected this year.
  • BioNTech aims to become a multi-product oncology company by 2030, maintaining its long-term growth strategy despite recent founder departures.
  • The company is expanding corporate governance with a proposal to put an eight-member supervisory board to a vote at the annual general meeting in May.
Risk Factors
  • BioNTech recently lowered its 2026 revenue forecast, indicating weaker near-term financial prospects.
  • Both founders of the company are departing at year-end, creating significant leadership and strategic uncertainty for investors.
  • The stock trades well below its 52-week high of €101.90, suggesting continued bearish sentiment or undervalued performance despite recent gains.
  • BioNTech faces ongoing unresolved legal disputes, including Moderna's 2022 lawsuit over Comirnaty that remains unsettled, posing potential long-term financial liabilities.
  • Meaningful oncology revenue is not anticipated until after 2026, leaving the company reliant on COVID vaccine income in the near term while competing against other pharma heavyweights for historic revenue streams.
  • A proposal to expand the supervisory board from seven to eight members will be voted on at the annual general meeting, which could signal internal governance instability or need for external expertise.
Full Analysis
BioNTech is generating significant headlines with dual momentum in its oncology pipeline and an escalating legal strategy against competitors. At the AACR Annual Meeting 2026, the company presented updated Phase 1 data for its personalized mRNA cancer vaccine, Autogene Cevumeran (BNT122), developed in collaboration with Genentech. The trial focused on pancreatic ductal adenocarcinoma, a malignancy with an American Cancer Society-quoted five-year survival rate of approximately 13 percent. Outcomes were highly divergent based on immune response; among eight patients showing an immune response, seven remained alive six years post-surgery with an 87.5 percent survival rate at the last follow-up. In contrast, non-responders saw only a 25 percent survival rate with a median overall survival of 3.4 years and relapse after a median of 13.4 months. The data highlighted the potential durability of the T-cells triggered by the vaccine, which have an estimated average lifespan of 7.7 years, while the treatment involves doses custom-manufactured from patient tumor DNA profiles encoding up to 20 neoantigens. On the legal front, BioNTech’s subsidiary CureVac filed a patent infringement lawsuit in Delaware federal court against Moderna regarding the stabilization of messenger RNA used in the development of Spikevax. This move follows a separate suit initiated by BioNTech in February targeting Moderna’s mNEXSPIKE vaccine, amid a broader landscape where other pharmaceutical giants are also vying for share of COVID-19 vaccine revenue and disputes remain unresolved over earlier litigation involving Pfizer’s Comirnaty. The company aims to become a multi-product oncology company by 2030, with plans to run 15 Phase 3 oncology studies by the end of 2026 and anticipate meaningful oncology revenue after that period. Investors are observing BioNTech as its stock trades well below its 52-week high of €101.90 but has recovered to close Friday at €88.75, marking a roughly 16 percent gain over the past month after pressure from a lowered 2026 revenue forecast and the announced departure of both founders by year-end. Wall Street maintains a consensus "Moderate Buy" rating with an average price target of $133, while the company looks toward May for Q1 results on May 5 and an annual general meeting where shareholders will vote on expanding the supervisory board to eight members to bolster oncology and clinical development expertise. Despite these promising scientific milestones and corporate developments, long-term revenue realization from its oncology portfolio remains dependent on the successful progression of upcoming trials and the resolution of ongoing intellectual property battles that could shape the mRNA sector’s future revenue streams.